TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma

Hui Huang Lai, Chih Wei Li, Chih Chen Hong, Hung Yu Sun, Ching Feng Chiu, Da Liang Ou, Pai Sheng Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer-related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor. The multikinase inhibitor sorafenib is the first-line treatment for patients with advanced HCC. However, cases of primary or acquired resistance to sorafenib have gradually increased, leading to a predicament in HCC therapy. Thus, it is critical to investigate the mechanism underlying sorafenib resistance. Transactivation response element RNA-binding protein 2 (TARBP2) is a multifaceted miRNA biogenesis factor that regulates cancer stem cell (CSC) properties. The tumorigenicity and drug resistance of cancer cells are often enhanced due to the acquisition of CSC features. However, the role of TARBP2 in sorafenib resistance in HCC remains unknown. Our results demonstrate that TARBP2 is significantly downregulated in sorafenib-resistant HCC cells. The TARBP2 protein was destabilized through autophagic–lysosomal proteolysis, thereby stabilizing the expression of the CSC marker protein Nanog, which facilitates sorafenib resistance in HCC cells. In summary, here we reveal a novel miRNA-independent role of TARBP2 in regulating sorafenib resistance in HCC cells.

Original languageEnglish
Pages (from-to)928-945
Number of pages18
JournalMolecular Oncology
Volume13
Issue number4
DOIs
Publication statusPublished - 2019 Apr

Fingerprint

RNA-Binding Proteins
Response Elements
Transcriptional Activation
Hepatocellular Carcinoma
Neoplastic Stem Cells
MicroRNAs
Neoplasms
sorafenib
Drug Resistance
Proteolysis
Down-Regulation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Cite this

Lai, Hui Huang ; Li, Chih Wei ; Hong, Chih Chen ; Sun, Hung Yu ; Chiu, Ching Feng ; Ou, Da Liang ; Chen, Pai Sheng. / TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. In: Molecular Oncology. 2019 ; Vol. 13, No. 4. pp. 928-945.
@article{7e62858d5ae5456489341973c935e90c,
title = "TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer-related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor. The multikinase inhibitor sorafenib is the first-line treatment for patients with advanced HCC. However, cases of primary or acquired resistance to sorafenib have gradually increased, leading to a predicament in HCC therapy. Thus, it is critical to investigate the mechanism underlying sorafenib resistance. Transactivation response element RNA-binding protein 2 (TARBP2) is a multifaceted miRNA biogenesis factor that regulates cancer stem cell (CSC) properties. The tumorigenicity and drug resistance of cancer cells are often enhanced due to the acquisition of CSC features. However, the role of TARBP2 in sorafenib resistance in HCC remains unknown. Our results demonstrate that TARBP2 is significantly downregulated in sorafenib-resistant HCC cells. The TARBP2 protein was destabilized through autophagic–lysosomal proteolysis, thereby stabilizing the expression of the CSC marker protein Nanog, which facilitates sorafenib resistance in HCC cells. In summary, here we reveal a novel miRNA-independent role of TARBP2 in regulating sorafenib resistance in HCC cells.",
author = "Lai, {Hui Huang} and Li, {Chih Wei} and Hong, {Chih Chen} and Sun, {Hung Yu} and Chiu, {Ching Feng} and Ou, {Da Liang} and Chen, {Pai Sheng}",
year = "2019",
month = "4",
doi = "10.1002/1878-0261.12449",
language = "English",
volume = "13",
pages = "928--945",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "4",

}

TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. / Lai, Hui Huang; Li, Chih Wei; Hong, Chih Chen; Sun, Hung Yu; Chiu, Ching Feng; Ou, Da Liang; Chen, Pai Sheng.

In: Molecular Oncology, Vol. 13, No. 4, 04.2019, p. 928-945.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma

AU - Lai, Hui Huang

AU - Li, Chih Wei

AU - Hong, Chih Chen

AU - Sun, Hung Yu

AU - Chiu, Ching Feng

AU - Ou, Da Liang

AU - Chen, Pai Sheng

PY - 2019/4

Y1 - 2019/4

N2 - Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer-related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor. The multikinase inhibitor sorafenib is the first-line treatment for patients with advanced HCC. However, cases of primary or acquired resistance to sorafenib have gradually increased, leading to a predicament in HCC therapy. Thus, it is critical to investigate the mechanism underlying sorafenib resistance. Transactivation response element RNA-binding protein 2 (TARBP2) is a multifaceted miRNA biogenesis factor that regulates cancer stem cell (CSC) properties. The tumorigenicity and drug resistance of cancer cells are often enhanced due to the acquisition of CSC features. However, the role of TARBP2 in sorafenib resistance in HCC remains unknown. Our results demonstrate that TARBP2 is significantly downregulated in sorafenib-resistant HCC cells. The TARBP2 protein was destabilized through autophagic–lysosomal proteolysis, thereby stabilizing the expression of the CSC marker protein Nanog, which facilitates sorafenib resistance in HCC cells. In summary, here we reveal a novel miRNA-independent role of TARBP2 in regulating sorafenib resistance in HCC cells.

AB - Hepatocellular carcinoma (HCC) is a lethal human malignancy and a leading cause of cancer-related death worldwide. Patients with HCC are often diagnosed at an advanced stage, and the prognosis is usually poor. The multikinase inhibitor sorafenib is the first-line treatment for patients with advanced HCC. However, cases of primary or acquired resistance to sorafenib have gradually increased, leading to a predicament in HCC therapy. Thus, it is critical to investigate the mechanism underlying sorafenib resistance. Transactivation response element RNA-binding protein 2 (TARBP2) is a multifaceted miRNA biogenesis factor that regulates cancer stem cell (CSC) properties. The tumorigenicity and drug resistance of cancer cells are often enhanced due to the acquisition of CSC features. However, the role of TARBP2 in sorafenib resistance in HCC remains unknown. Our results demonstrate that TARBP2 is significantly downregulated in sorafenib-resistant HCC cells. The TARBP2 protein was destabilized through autophagic–lysosomal proteolysis, thereby stabilizing the expression of the CSC marker protein Nanog, which facilitates sorafenib resistance in HCC cells. In summary, here we reveal a novel miRNA-independent role of TARBP2 in regulating sorafenib resistance in HCC cells.

UR - http://www.scopus.com/inward/record.url?scp=85062391008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062391008&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12449

DO - 10.1002/1878-0261.12449

M3 - Article

C2 - 30657254

AN - SCOPUS:85062391008

VL - 13

SP - 928

EP - 945

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 4

ER -